Jefferies Group Comments on Danaher Co.’s Q1 2018 Earnings (DHR)

Danaher Co. (NYSE:DHR) – Equities researchers at Jefferies Group lowered their Q1 2018 earnings per share (EPS) estimates for shares of Danaher in a research report issued on Thursday. Jefferies Group analyst B. Couillard now expects that the conglomerate will post earnings of $0.91 per share for the quarter, down from their prior forecast of $1.01. Jefferies Group also issued estimates for Danaher’s Q2 2018 earnings at $1.09 EPS and Q4 2018 earnings at $1.30 EPS.

A number of other research firms also recently weighed in on DHR. Citigroup boosted their target price on Danaher to $107.00 and gave the stock a “buy” rating in a research report on Friday. Goldman Sachs Group restated a “neutral” rating and issued a $83.00 target price on shares of Danaher in a research report on Tuesday, September 26th. Credit Suisse Group boosted their target price on Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. J P Morgan Chase & Co restated an “overweight” rating and issued a $95.00 target price on shares of Danaher in a research report on Friday, September 8th. Finally, Robert W. Baird boosted their target price on Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $94.05.

Shares of Danaher (NYSE:DHR) opened at $94.00 on Monday. The firm has a market capitalization of $65,386.87, a P/E ratio of 24.16, a P/E/G ratio of 2.24 and a beta of 1.02. Danaher has a 12-month low of $77.66 and a 12-month high of $94.82. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00.

Danaher (NYSE:DHR) last released its earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a return on equity of 11.29% and a net margin of 13.36%. Danaher’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Institutional investors have recently made changes to their positions in the stock. ETRADE Capital Management LLC raised its holdings in shares of Danaher by 5.1% during the second quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after acquiring an additional 917 shares in the last quarter. Honeywell International Inc. bought a new position in shares of Danaher during the second quarter valued at approximately $25,317,000. Roundview Capital LLC raised its holdings in shares of Danaher by 2.0% during the second quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after acquiring an additional 502 shares in the last quarter. Eastern Bank raised its holdings in shares of Danaher by 4,291.1% during the second quarter. Eastern Bank now owns 128,001 shares of the conglomerate’s stock valued at $10,802,000 after acquiring an additional 125,086 shares in the last quarter. Finally, Perkins Coie Trust Co raised its holdings in shares of Danaher by 2.0% during the second quarter. Perkins Coie Trust Co now owns 29,431 shares of the conglomerate’s stock valued at $2,484,000 after acquiring an additional 586 shares in the last quarter. Institutional investors own 76.32% of the company’s stock.

In other Danaher news, Director Donald J. Ehrlich sold 10,578 shares of the business’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the sale, the director now owns 104,621 shares in the company, valued at $9,501,679.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Robert S. Lutz sold 11,189 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total value of $1,025,583.74. Following the completion of the sale, the chief accounting officer now owns 18,314 shares of the company’s stock, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. Insiders sold 273,810 shares of company stock valued at $25,218,813 in the last quarter. Corporate insiders own 12.20% of the company’s stock.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a $0.14 dividend. The ex-dividend date is Thursday, December 28th. This represents a $0.56 annualized dividend and a yield of 0.60%. Danaher’s payout ratio is currently 16.52%.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://ledgergazette.com/2017/12/18/jefferies-group-comments-on-danaher-co-s-q1-2018-earnings-dhr.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Earnings History and Estimates for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply